A test which uses artificial intelligence to measure proteins present in some patients with advanced bowel cancer could hold the key to more targeted treatment.
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
